Melatonin during androgen-deprivation therapy: supportive care is not cancer treatment
Small trials examine sleep, mood and hot flashes during prostate-cancer treatment; they do not show that melatonin controls the cancer.

Melatonin may be studied for treatment-related symptoms, but supportive-care findings must not be turned into prostate-cancer claims.
Androgen deprivation can affect more than the tumor
Androgen-deprivation therapy, or ADT, can be an important part of prostate-cancer care. It can also affect sleep, mood, sexual health, body composition and hot flashes. Supportive-care studies ask whether an additional intervention helps those experiences while cancer treatment continues.
A 2023 randomized double-blind placebo-controlled trial studied melatonin for mood and sleep problems in men receiving ADT. This is a different question from whether melatonin slows prostate cancer. The participants continued cancer care; melatonin was evaluated for treatment-associated symptoms.

A symptom benefit does not become an anticancer effect
Sleep quality and mood matter greatly, but improvement in those outcomes does not show reduced PSA, delayed progression or longer survival. A supplement can be useful for supportive care without being cancer therapy. Keeping that boundary clear protects both accurate expectations and adherence to proven treatment.
Laboratory studies of melatonin receptors or prostate-cancer cells may explain why researchers remain interested in the hormone. Cell and animal findings cannot establish an anticancer dose or benefit in people.
Newer trials still require context
A 2026 randomized trial examined melatonin for hot flashes and sexual-health outcomes during ADT. Its recent publication makes it relevant to current supportive-care discussions, but one study does not define a universal regimen. Dose, duration, baseline sleep problems and concurrent treatments influence applicability.
A 2026 systematic review of melatonin for sleep disorders across cancer populations found mixed results depending on the sleep outcome and trial. Evidence across different cancers and treatments should not be treated as prostate-specific proof.
Timing and product quality matter
Melatonin affects circadian signaling, so timing can matter as much as the amount. Products also vary in formulation and actual content. Taking more because sleep remains difficult can increase next-day drowsiness or other adverse effects without solving the underlying problem.
Sleep disruption during ADT can also have multiple contributors, including hot flashes, nocturia, anxiety, pain and sleep apnea. A supplement-first approach may miss the symptom that most needs targeted treatment.
Build a coordinated symptom plan
Men receiving ADT should discuss sleep and mood changes with the oncology team rather than assuming they are unavoidable. The review can include medicines, alcohol, cannabis, other sleep supplements and the timing of symptoms. Severe depression or thoughts of self-harm require urgent professional help.
Melatonin may have a role for selected treatment-related symptoms, but the evidence does not support replacing ADT, altering its schedule or describing melatonin as prostate-cancer control. Supportive care is valuable precisely because it addresses quality of life while evidence-based cancer care continues.

How to evaluate an ADT sleep-supplement claim
Look for a randomized placebo comparison in men receiving similar cancer treatment, then identify the sleep scale, treatment duration and adverse-event reporting. Check whether the study measured cancer outcomes at all. If a product moves from better sleep to immune, testosterone or tumor claims, the conclusion has crossed into a different question. A responsible summary can be optimistic about symptom support while remaining explicit that cancer control was not shown.
Sleep care can extend beyond a supplement
A useful assessment asks when awakenings occur, whether hot flashes precede them, whether the person snores or gasps, and how daytime function has changed. Cognitive behavioral therapy for insomnia, treatment of sleep apnea, temperature management, medication review and timing changes may address causes that melatonin does not. Mood symptoms during ADT also deserve direct attention rather than being folded into poor sleep. The goal is not to force a supplement to solve every nighttime problem; it is to identify the problem accurately and choose the least burdensome effective response while cancer treatment continues.
The lowest useful dose is not a universal number
Melatonin trials use different doses and schedules, and commercial products may contain more or less than their labels suggest. A higher dose is not automatically more effective for sleep and may increase vivid dreams, morning sedation or dizziness. Dose and timing should be individualized with the treatment team, especially when other sedating medicines or fall risks are present.
Sources & further reading
- Melatonin in the management of mood and sleep problems induced by androgen-deprivation therapy: a randomized trial ↗
- Targeting side effects associated with androgen-deprivation therapy using melatonin: a randomized trial ↗
- Safety and efficacy of melatonin for sleep disorders in cancer: a systematic review and meta-analysis ↗
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.